Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Gracell Biotechnologies Inc. American Depositary Shares (GRCL)

https://www.gracellbio.com

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/08/2021

Market Cap

989,867,100

Shares Outstanding

479,630,000

Weighted SO

96,572,377

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

THRX --.--%

GLUE --.--%

DSGN --.--%

ERAS --.--%

NXTC --.--%

CTMX --.--%

NLTX --.--%

SPRO --.--%

ASMB --.--%

Beta

-0.3450

Last Div

0.0000

Range

1.4-10.435

Chg

0.0050

Avg Vol

1464475

Mkt Cap

989867100

Exch

NASDAQ

Country

CN

Phone

86 512 6262 6701

DCF Diff

8.6064

DCF

1.6436

Div Yield

0.0000

P/S

0.0000

EV Multiple

-10.5297

P/FV

3.8017

Div Yield %

0.0000

P/E

-12.4006

PEG

-0.6140

Payout

0.0000

Current Ratio

7.7317

Quick Ratio

7.4424

Cash Ratio

7.3096

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0001

ROA

-0.2630

ROE

-0.3720

ROCE

-0.3486

NI/EBT

1.0001

EBT/EBIT

0.8585

EBIT/Rev

0.0000

Debt Ratio

0.0613

D/E

0.0714

LT Debt/Cap

0.0214

Total Debt/Cap

0.0667

Int Coverage

-89.8657

CF/Debt

0.0000

Equity Multi

1.1659

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

20.3499

OCF/Sales

0.0000

FCF/OCF

0.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

3.8017

P/B

3.8017

P/S

0.0000

P/E

-12.4006

P/FCF

0.0000

P/OCF

0.0000

P/CF

0.0000

PEG

-0.6140

P/S

0.0000

EV Multiple

-10.5297

P/FV

3.8017

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Benzinga Dec 26, 12:20 Crude Oil Rises Over 3%; US Home Prices Increase In October Benzinga Dec 26, 12:20 Crude Oil Rises Over 3%; US Home Prices Increase In October MarketWatch Dec 26, 09:34 A new all-time high awaits the S&P 500 as investors 'buy into the euphoria,' says this strategist MarketWatch Dec 26, 09:34 A new all-time high awaits the S&P 500 as investors 'buy into the euphoria,' says this strategist MarketWatch Dec 26, 08:06 A new all-time high awaits the S&P 500 as investors 'buy into the euphoria,' says this strategist Benzinga Dec 26, 07:22 US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs MarketWatch Dec 26, 07:07 A new all-time high awaits the S&P 500 as investors 'buy into the euphoria,' says this strategist GlobeNewswire Inc. Dec 26, 02:00 亘喜生物宣布与阿斯利康达成收购协议，展望细胞疗法治疗癌症和自身免疫性疾病新征程 GlobeNewswire Inc. Dec 26, 02:00 Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases GlobeNewswire Inc. Dec 26, 02:00 亘喜生物宣布与阿斯利康达成收购协议，展望细胞疗法治疗癌症和自身免疫性疾病新征程 GlobeNewswire Inc. Dec 26, 02:00 Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Revenue Product Segmentation